A5060655132- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Neuroblastoma Research and Treatments
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Hematological disorders and diagnostics
- Chronic Lymphocytic Leukemia Research
- Blood groups and transfusion
- Autoimmune and Inflammatory Disorders Research
- Lung Cancer Treatments and Mutations
- Platelet Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Lung Cancer Research Studies
- Pleural and Pulmonary Diseases
- Chronic Myeloid Leukemia Treatments
- Inflammasome and immune disorders
- Gastrointestinal disorders and treatments
- Dermatology and Skin Diseases
Azienda USL di Bologna
2021-2024
University of Bologna
2010-2022
Istituti di Ricovero e Cura a Carattere Scientifico
1995-2022
Policlinico S.Orsola-Malpighi
2008-2021
European School of Oncology
2017
Associazione Italiana Ematologia Oncologia Pediatrica
1998-2009
University of Pavia
1998-2005
Italian Association for Cancer Research
2004
University of Pisa
1998-2002
Istituto Giannina Gaslini
1992-2000
PURPOSE This study was conducted to assess the comparative values of allogeneic bone marrow transplantation (BMT) and autologous (ABMT) with sequential postremission chemotherapy (SPC) in children acute myelogenous leukemia (AML) first remission. PATIENTS AND METHODS From March 1987 1990, 161 assessable patients younger than 15 years age newly diagnosed AML were treated uniformly two courses daunorubicin standard-dose cytarabine. After initial consolidation a course daunorubicin, cytarabine,...
To identify the prognostic factors, treatment, and outcome of children affected by renal cell carcinoma (RCC).The series included 41 patients (18 males 23 females) with a median age 124 months observed at 11 Italian Association for Pediatric Hematology Oncology centers from January 1973 to 2001. Clinical data, surgical notes, pathologic findings, summaries therapy were taken charts.Seven (17%) had papillary histology, 34 (82.4%) nonpapillary histology. Eighteen (43.9%) stage I, one patient...
In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, 142 newly diagnosed AML enrolled Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At end first induction course, MRD was <0·1% 69, 0·1-1% 16 and >1% 51 patients....
Background. Improved outcome of children with acute lymphoblastic leukemia (ALL) who received intensive chemotherapy was observed by the Italian Association for Pediatric Hematology Oncology (AIEOP). To verify if this improved also extended to T-cell (T-ALL) patients after introduction chemotherapy, treatment responses 2011 patients, including 184 T-ALL treated over decade 1982-1991, were analyzed. Further, potential use association presenting clinical and biologic features determine risk...
Transient hypogammaglobulinemia of infancy (THI) is a heterogeneous disorder characterized by reduced serum IgG levels in early infancy. A putative diagnosis initially made after exclusion other causes while definitive THI can only be posteriori patients with normalization levels. The aim this study to characterize clinical and immunological features children an initial correlation natural outcome, assess predictive laboratory parameters evolution for disorder. We prospectively analysed...
Background. Attempting to optimize treatment results in pediatric Hodgkin disease while minimizing major side effects, at least early-stage patients, 1983 the Italian Association of Pediatric Hematology and Oncology (AIEOP) conceived a multicenter study tailored according stage, bulky mediastinal mass, age. Methods. Between December, January, 1989, 215 evaluable patients (median age, 9.9 years, range, 1–15 years) received AIEOP-MH protocol low-dose radiation therapy (20–25 Gy), with three...